Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
出版年份 2015 全文链接
标题
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
作者
关键词
-
出版物
Biomed Research International
Volume 2015, Issue -, Pages 1-16
出版商
Hindawi Limited
发表日期
2015-06-11
DOI
10.1155/2015/851387
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer treatment and survivorship statistics, 2014
- (2014) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Analysis of the BRAF V600E mutation in primary cutaneous melanoma
- (2014) J.S.S. Inumaru et al. GENETICS AND MOLECULAR RESEARCH
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Pembrolizumab for treatment of refractory melanoma
- (2014) Sanjeet Bagcchi LANCET ONCOLOGY
- Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma
- (2014) Darshil J. Shah et al. MAYO CLINIC PROCEEDINGS
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma
- (2014) Richard Joseph et al. Drug Design Development and Therapy
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
- (2013) K. L. Nathanson et al. CLINICAL CANCER RESEARCH
- Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date
- (2013) Charlotte Lemech et al. DRUGS
- Trametinib: First Global Approval
- (2013) Cameron J. M. Wright et al. DRUGS
- Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
- (2013) Alexander M. Menzies et al. EUROPEAN JOURNAL OF CANCER
- Resistance to BRAF-targeted therapy in melanoma
- (2013) Ryan J. Sullivan et al. EUROPEAN JOURNAL OF CANCER
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
- (2013) Caroline Robert et al. LANCET ONCOLOGY
- Lambrolizumab induces advanced melanoma regression
- (2013) Talha Khan Burki LANCET ONCOLOGY
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- New combinations and immunotherapies for melanoma: latest evidence and clinical utility
- (2013) Alexander M. Menzies et al. Therapeutic Advances in Medical Oncology
- The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
- (2012) S V Holt et al. BRITISH JOURNAL OF CANCER
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002)
- (2012) Jeong-Yeol Park et al. EUROPEAN JOURNAL OF CANCER
- The role of BRAF V600 mutation in melanoma
- (2012) Paolo A Ascierto et al. Journal of Translational Medicine
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Tumor Immunotherapy Directed at PD-1
- (2012) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Dabrafenib and its potential for the treatment of metastatic melanoma
- (2012) Rajmohan Murali et al. Drug Design Development and Therapy
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease
- (2011) A. Vultur et al. CLINICAL CANCER RESEARCH
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
- (2011) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF as therapeutic target in melanoma
- (2010) Claudia Wellbrock et al. BIOCHEMICAL PHARMACOLOGY
- Targeting BRAF for patients with melanoma
- (2010) H-T Arkenau et al. BRITISH JOURNAL OF CANCER
- Malignant melanoma: Molecular cytogenetics and their implications in clinical medicine
- (2010) Jacqueline M. Junkins-Hopkins JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- (2009) Luis H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
- The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel
- (2008) N. K. Haass et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now